Generic Name and Formulations:
Acetohydroxamic acid 250mg; tabs.
Mission Pharmacal Company
Indications for LITHOSTAT:
As adjunctive therapy in chronic urea-splitting urinary infection.
Initially 12mg/kg per day every 6–8hrs; max 1.5g/day. Renal impairment: serum creatinine >1.8mg/dL: take at every 12-hour intervals; max 1g/day.
Initially 10mg/kg per day; monitor. Titrate doses to obtain therapeutic effects.
Disease and physical state amenable to surgery and antimicrobials. Urine infected by non-urease producing organisms. Infections controllable by oral antimicrobials. Renal dysfunction (CrCl <20mL/min, serum creatinine >2.5mg/dL). Females with unsatisfactory method of contraception. Pregnancy (Cat.X).
Severe renal impairment: monitor and consider reduced dose. Monitor liver function. Preexisting thrombophlebitis or phlebothrombosis. Monitor and obtain CBCs with reticulocytes after 2 weeks of therapy and every 3 months thereafter; if reticulocytes >6%, consider reduced dose. Nursing mothers: not recommended.
Rash with concomitant alcohol. Concomitant dietary iron: may reduce absorption of both acetohydroxamic acid and iron (use IM inj form, if needed).
Mild headaches, tremulousness, nervousness, depression, anxiety, GI upset, hemolytic anemia, mild reticulocytosis without anemia, rash, alopecia, phlebitis, palpitations.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|